nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo searchdiv qikanlogo popupnotification paper paperNew
2025, 17, v.66 1754-1758
房定亚基于络病理论分期论治结缔组织病伴免疫性血小板减少症经验
基金项目(Foundation): 北京市中医管理局北京中医药薪火传承“新3+3”工程(2023-SZ-F-27); 中国中医科学院科技创新工程重大攻关项目(CI2021A015);中国中医科学院科技创新工程创新团队(CI2021B007); 中国中医科学院西苑医院名老中医经验传承研究专项(XYZX0101-47)
邮箱(Email): anjanette49@126.com;
DOI: 10.13288/j.11-2166/r.2025.17.004
摘要:

总结房定亚基于络病理论分期论治结缔组织病伴免疫性血小板减少症的经验。认为络脉受损是本病的基本病机,急性期以热毒伤络、血溢脉外为病机关键,治以清络解毒,凉血散血,方选犀角地黄汤加减;慢性期气血不充、络虚失荣,治宜益气养血,护脉通络,方用归脾汤化裁。久病入络,瘀结最深,非通不达,故化瘀通络法贯穿治疗全程。

Abstract:

This paper is to summarize professor FANG Dingya's clinical experience in staged differentiation and treatment of connective tissue disease with immune thrombocytopenia(CTD-ITP) based on collateral disease theory. It is believed that the fundamental pathological feature is collateral vessel impairment. During the acute stage, the key pathogenesis lies in heat-toxin damaging collaterals, then blood extravasation outside the vessels, for which the treat-ment focuses on clearing collaterals and resolving toxins, cooling the blood and dissipating blood stasis, prescribing with modified Xijiao Dihuang Decoction (犀角地黄汤). During the chronic stage, characterized by deficiency of qi and blood, colla-terals failing to receive nourishment, the therapeutic principle shifts to tonifying qi and nourishing blood, protecting vessels and dredging collaterals, prescribing with modified Guipi Decoction (归脾汤). Considering that persis-tent illness penetrates deeply into collaterals leading to blood stasis accumulates, which cannot be resolved without dredging therapy, the stasis-dissolving and collateral-dredging method should be consistently applied throughout the entire treatment course.

参考文献

[1]莫颖倩,严青,叶霜,等.未分化结缔组织病和混合性结缔组织病的诊疗规范[J].中华内科杂志,2022,61(10):1119-1127.

[2]NEUNERT C, TERRELL DR, ARNOLD DM, et al.American society of hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv,2019,3(23):3829-3866.

[3]张燕,杨建英,王钦,等.原发性干燥综合征合并血细胞减少中医诊治研究进展[J].世界中医药,2024,19(2):250-255.

[4]马芳,周彩云,韩淑花,等.房定亚清络散血法治疗自身免疫性血管炎经验[J].北京中医药,2017,36(5):432-435.

[5]宋冬雪.结缔组织病合并血小板减少患者血常规各参数的分析研究[D].济宁:济宁医学院,2023.

[6]张薇.结缔组织病患者血小板减少的临床回顾性分析研究[D].南京:南京医科大学,2020.

[7]张颖,杨怡坤,王卫霞.房定亚风湿病专方专药要略[M].北京:北京科学技术出版社,2016:26.

[8]李秋钰,代妮妮,吕烨.系统性红斑狼疮的遗传学研究进展[J].国际泌尿系统杂志,2022,42(5):956-959.

[9]曹林娟,陈沙娜,乌兰图雅,等.以血小板减少为首发症状的结缔组织病与免疫性血小板减少性紫癜的鉴别诊断[J].实用检验医师杂志,2016,8(1):41-44.

[10]GONZALEZ-LOPEZ TJ, PROVAN D, BAREZ A, et al.Primary and secondary immune thrombocytopenia(ITP):time for a rethink[J]. Blood Rev,2023,61:101112.doi:10. 1016/j. blre. 2023. 101112.

[11]韩姗姗,代彦林,丁樱,等.从“治虚三本二统”论治免疫抑制剂毒副作用的思路探微[J].北京中医药大学学报,2023,46(4):450-455.

[12]王俊荣,刘风真,吕长俊,等.水牛角粉治疗难治性特发性血小板减少性紫癜的临床研究[J].滨州医学院学报,2001,24(5):486-487.

[13]胡哲,胡辉,杨舟,等.犀角地黄汤治疗ITP的疗效及其作用机制[J].中国老年学杂志,2023,43(24):6096-6100.

[14]张楚洁,刘慧萍,杨璐瑜,等.归脾汤有效成分与现代药理学的关联性[J].中成药,2020,42(6):1553-1558.

[15]鲁清浪,凌娜.紫河车的活性成分、药理作用及临床应用研究进展[J].中华中医药学刊,2024,42(11):232-236.

[16]刘文禹.归脾汤合二至丸治疗系统性红斑狼疮合并慢性病性贫血的临床研究[D].武汉:湖北中医药大学,2020.

[17]权学莲,刘春霞,曹翠芳,等.大菟丝子饮加减联合糖皮质激素治疗免疫性血小板减少性紫癜临床研究[J].新中医,2020,52(20):56-59.

[18]韩彩芝,余素清,魏丽君,等.紫河车的免疫调节作用[J].河北中医,1996,18(2):34-35.

基本信息:

DOI:10.13288/j.11-2166/r.2025.17.004

中图分类号:R249;R259

引用信息:

[1]李转转,唐今扬,王鑫等.房定亚基于络病理论分期论治结缔组织病伴免疫性血小板减少症经验[J].中医杂志,2025,66(17):1754-1758.DOI:10.13288/j.11-2166/r.2025.17.004.

基金信息:

北京市中医管理局北京中医药薪火传承“新3+3”工程(2023-SZ-F-27); 中国中医科学院科技创新工程重大攻关项目(CI2021A015);中国中医科学院科技创新工程创新团队(CI2021B007); 中国中医科学院西苑医院名老中医经验传承研究专项(XYZX0101-47)

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文